A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/178/a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT04991480 (https://clinicaltrials.gov/show/NCT04991480)

Advanced solid tumors

Study Contact Information:

Study coordinator:
Michael Courtland
[email protected]

About the Study

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral, targeted therapy that is designed to keep cancer cells from repairing DNA damage.

This study is no longer recruiting patients.

This Study is Open To:

This study is no longer recruiting patients.

This Study is Not Open To:

This study is no longer recruiting patients.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.